Company news
Humacyte, Inc. news in 2024
Humacyte, Inc.'s news releases, calls and decks from 2024, newest first.
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
December 18, 2024
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
November 21, 2024
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
November 17, 2024
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
November 13, 2024
Humacyte Third Quarter 2024 Financial Results and Business Update
November 7, 2024
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
October 27, 2024
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
October 22, 2024
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
October 3, 2024
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
September 18, 2024
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
August 26, 2024
Humacyte Second Quarter 2024 Financial Results and Business Update
August 12, 2024
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
August 8, 2024
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis
July 30, 2024
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
July 15, 2024
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
June 30, 2024
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
June 24, 2024
Humacyte First Quarter 2024 Financial Results and Business Update
May 9, 2024
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
March 21, 2024
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
February 28, 2024
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
February 8, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (February 2024)
Investor deck · 41 slides · Feb 29, 2024